A Multi-Center Trial of the ProLung Test™
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The primary Study hypothesis is that the ProLung Test will demonstrate safety and efficacy in the risk stratification of patients with pulmonary lesions identified by CT that are suspicious for lung cancer. A statistically significant result will indicate that patients with a high ProLung Test result have a greater risk of developing lung cancer than patients with a low test result.
There are three Specific Aims of this study:
- Optimize and confirm the stability of the ProLung Test risk-stratification algorithm in patients with tissue diagnosis.
- Externally validate the efficacy of the ProLung Test risk-stratification algorithm by comparing the test result to the conclusive tissue patient diagnosis.
- Assess the safety and tolerability of the ProLung Test procedures.
Study Design This Study consists of two distinct phases, Stabilization and Validation. The Study will collect data from multiple sites (3 to 12), and each site may enroll patients and collect data for the Stabilization and Validation Phases with a minimum of three sites for the Validation Phase.
| Condition |
|---|
|
Solitary Pulmonary Nodule Multiple Pulmonary Nodules |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | A Multi-Center Trial of the ProLung Test™ (Transthoracic Bioconductance Measurement) as an Adjunct to CT Chest Scans for the Risk Stratification of Patients With Pulmonary Lesions Suspicious for Lung Cancer |
- Clinical Efficacy in the risk stratification of patients with indeterminate lesions [ Time Frame: The ProLung Test will be performed on patients prior to their indicated biopsy and evaluated against conclusive post biopsy pathology results ] [ Designated as safety issue: Yes ]Demonstrate safety and efficacy in the risk stratification of patients with pulmonary lesions identified by CT that are suspicous for lung cancer.
| Estimated Enrollment: | 300 |
| Study Start Date: | October 2012 |
| Estimated Study Completion Date: | April 2013 |
| Estimated Primary Completion Date: | April 2013 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Patients with Pulmonary Lesions
Patients with Pulmonary Lesions as seen by CT
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Subjects with pulmonary lesions suspicious for lung cancer
Inclusion Criteria
Subjects who meet all of the following criteria may be enrolled in this Study:
- Subject is male or female, age 18 or older.
- Subject has undergone CT scan of the lung(s) that indicates one or more non-calcified nodules or lesions suspicious for lung cancer.
- Subject's pulmonary nodule or lesion is greater than 4mm. Size is determined by the largest nodule or lesion dimension identified from CT imaging.
- Subject is indicated for a tissue biopsy of the lung.
- Subject must be able to receive a ProLung Test within 60 days of abnormal CT (Inclusion Criterion 2 & 3) or within 60 days prior to the tissue biopsy (Inclusion Criterion 4).
- Subject is capable of understanding and agreeing to fulfill the requirements of this Protocol.
- Subject has signed the IRB/IEC approved Informed Consent Form ("ICF").
Exclusion Criteria
The following criteria will disqualify a subject from enrollment into this Study:
- Subject has an implanted electronic device in the chest.
- Subject receiving therapy for suspected chest infection such as fungal infection or tuberculosis.
- Subject with diagnosed malignancy within the past 5 (five) years except for non-melanoma skin cancer and lung cancer.
- Subject has received systemic corticosteroid medication within 14 days prior to ProLung Test (except for ophthalmic preparations or inhaled medications used more than 4 hours prior to ProLung Test).
- Subject has received an invasive medical or surgical procedure within the thoracic cavity within 30 days prior to the ProLung Test or within the previous 14 days for a bronchoscopic procedure.
- Subject presents with an anomalous physical or anatomical condition that precludes ProLung Test measurement.
- Subject will have undergone unusually strenuous exercise within 24 hours.
- Subject who has significant systemic diseases such as uncontrolled diabetes, advanced heart failure, or a recent myocardial infarction, or other medical condition such as severe morbid obesity that in the judgment of the Principal Investigator would make him/her unsuitable for the Study.
Contacts and Locations| Contact: Michael A Garff, BS, MBA | 8012049625 | mag@prolung.com |
| United States, California | |
| UCLA | Recruiting |
| LA, California, United States, 90024 | |
| Contact: Polly Kay, R.N. 310-794-0376 pkay@mednet.ucla.edu | |
| Contact: Andrea Oh, MD 3107948956 aoh@mednet.ucla.edu | |
| Sub-Investigator: Denise Aberle, MD | |
| Principal Investigator: Fereidoun Abtin, MD | |
| United States, Michigan | |
| Henry Ford Medical Center | Not yet recruiting |
| Detroit, Michigan, United States, 48202 | |
| Contact: Marcie Major, R.N., B.S.N. 313-916-2433 MMAJOR1@hfhs.org | |
| Contact: Michael Simoff, MD 313-916-2433 msimoff@hfhs.org | |
| Principal Investigator: Michael Simoff, MD | |
| United States, Utah | |
| Huntsman Cancer Institute | Recruiting |
| SLC, Utah, United States, 84112 | |
| Contact: Nicole Mauerman, MS 801-587-3095 nicole.mauerman@hci.utah.edu | |
| Principal Investigator: Chakravarthy Reddy, MD | |
| Principal Investigator: | Rex C Yung, MD | Johns Hopkins Medical Center |
| Principal Investigator: | Denise R. Aberle, MD | UCLA Radiological Sciences Section of Thoracic Imaging |
| Principal Investigator: | Chakravarthy Reddy, MD | Huntsman Cancer Institute |
| Principal Investigator: | Michael Simoff, MD | Henry Ford Health System |
More Information
No publications provided
| Responsible Party: | Fresh Medical Laboratories |
| ClinicalTrials.gov Identifier: | NCT01566682 History of Changes |
| Other Study ID Numbers: | PL-208 |
| Study First Received: | March 27, 2012 |
| Last Updated: | January 4, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Fresh Medical Laboratories:
|
Lung Lesion Lung Mass Lung Nodule Lung Cancer Low-Dose CT |
CT Diagnostic Evaluation Bioconductance ProLung |
Additional relevant MeSH terms:
|
Lung Neoplasms Multiple Pulmonary Nodules Solitary Pulmonary Nodule Respiratory Tract Neoplasms Thoracic Neoplasms |
Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases |
ClinicalTrials.gov processed this record on May 21, 2013